<p>BioVaxys Technology Corp. has announced positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) in combination with pembrolizumab and low-dose cyclophosphamide in patients with advanced or metastatic bladder cancer. The results, which have already been presented, showed that of 17 evaluable subjects, five demonstrated objective responses, including two confirmed complete responses and three partial responses. The study included patients who had previously progressed on anti-PD1/PD-L1 therapies. These data build on previous Phase 1B/2 findings in advanced ovarian cancer and support the further development of MVP-S in combination with checkpoint inhibitors across multiple solid tumor indications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovaxys Technology Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 1LymFYXnw) on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

<p>BioVaxys Technology Corp. has reported positive Phase 2 results for maveropepimut-S (MVP-S) in combination with pembrolizumab and low-dose cyclophosphamide for metastatic bladder cancer. In a study of 17 patients, five showed objective responses, including two complete and three partial responses. These findings support further development of MVP-S with checkpoint inhibitors for various solid tumors. This news is generated by Public Technologies and is for informational purposes only, not financial or legal advice.</p>

Reuters

Guotai CSI Bio-medicine ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

E Fund CSI Biotechnology Theme ETF

Invesco Nasdaq Biotechnology ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

iShares Global Healthcare

iShares Biotechnology ETF

VanEck Biotech ETF

iShares US Pharma

Huaan Hang Seng Biotech ETF

Proshares UltraShort Nasdaq Biotech

Proshares Ultra Nasdaq Biotech

Minsheng Royal CSI Biotechnology Theme ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VG Health

BioVaxys Reports Positive Phase 2 Results for MVP-S Combo in Metastatic Bladder Cancer